Misplaced Pages

This is an old revision of this page, as edited by Rjwilmsi (talk | contribs) at 14:05, 19 February 2011 (Journal cites:, added 1 PMIDs, completed 1 page ranges, using AWB (7584)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Vorapaxar

Clinical data
Other names	SCH-530348
Identifiers
IUPAC name Ethyl N-vinyl]-3-methyl-1-oxo-3a,4,4a,5,6,7,8,8a,9,9a-decahydro-3H-benzoisobenzofuran-7-yl]carbamate
CAS Number	618385-01-6
PubChem CID	10077130
CompTox Dashboard (EPA)	DTXSID201009336
ECHA InfoCard	100.116.767
Chemical and physical data
Formula	C29H33FN2O4
Molar mass	492.58 g/mol g·mol

Vorapaxar (formerly SCH-530,348) is a thrombin receptor (PAR-1) antagonist based on the natural product himbacine. Discovered by Schering-Plough and currently being developed by Merck & Co., it is a experimental pharmaceutical treatment for acute coronary syndrome chest pain caused by coronary artery disease.

In January 2011, clinical trials being conducted by Merck were halted for patients with stroke and mild heart conditions. Merck is uncertain whether further development of vorapaxar will continue.

References

1. Samuel Chackalamannil (2008). "Discovery of a Novel, Orally Active Himbacine-Based Thrombin Receptor Antagonist (SCH 530348) with Potent Antiplatelet Activity". Journal of Medicinal Chemistry. 51 (11): 3061–4. doi:10.1021/jm800180e. PMID 18447380.
2. Merck Blood Thinner Studies Halted in Select Patients, Bloomberg News, January 13, 2011

External links

• C&EN
• ChemSpider Article

• Carbamates
• Pyridines
• Organofluorides
• Lactones